AKT1 and myalgic encephalomeyelitis/chronic fatigue syndrome: The BRD4 inhibitor JQ1 can act on the TGF-β1/SMAD family member 3 (SMAD3) and protein kinase B (AKT) signaling pathways, attenuating the expression of fibrogenic genes such as Tgf-β, Ctgf, Col1α1, Smad3, and other fibrogenic genes in high-glucose (HG)-induced CFs.